Ardigen, a global leader in artificial intelligence & bioinformatics for precision medicine, announces its collaboration with the DKFZ research groups, led by Prof. Michael Platten/ Dr. Edward Green, regarding safety assessments of TCR based therapies (TCR-Ts). As a part of […]
Read More>>March 24, 2022 – Ardigen, a global leader in artificial intelligence for drug discovery, is proud to announce that Lukasz Dutkiewicz, PhD has joined the company as Business Development Director of the Digital CRO division. He brings extensive knowledge […]
Read More>>Krakow, Poland, 04.11.2021. Ardigen, one of the world’s leading companies that utilizes artificial intelligence (AI) algorithms for drug discovery, announced that another distinguished scientist joined the company’s Scientific Advisory Board. Prof. Olivera Finn will support Ardigen’s work on AI-driven technology […]
Read More>>Ardigen received funding for development of AI-powered Microbiome Platform that will improve prediction of cancer therapies efficacy. Krakow, Poland, 25.10.2021. Ardigen- the world-leading company that utilizes Artificial Intelligence (AI) for drug discovery, has signed an agreement with the Polish National […]
Read More>>September 7, 2021 – Ardigen, one of the world-leading companies that utilizes artificial intelligence (AI) algorithms for drug discovery, is proud to announce that Dr. Aleksandra Walczak joined the company’s Scientific Council. With a PhD in physical sciences and her […]
Read More>>March 11, 2021 – Ardigen, a global leader in artificial intelligence for drug discovery, is proud to announce that Dr. Michał Warchoł has joined the company’s Board of Management as its 4th member. He brings extensive knowledge and experience in the […]
Read More>>